At the Clinical Trials on Alzheimer’s Disease Congress this week, Biogen (MA, USA) has provided a detailed report on the latest aducanumab results, including why there was such a difference in the results between ENGAGE and EMERGE.
This week in industry includes trials on elenbecestat to be discontinued, ofatumumab demonstrating superiority to Aubagio and the Toca 5 trial results failing to meet primary endpoint.
What have been the biggest headlines in industry this week? Take a look at our highlights including positive news about two monoclonal antibodies for relapsing multiple sclerosis and neuromyelitis optica spectrum disorder.
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
This week in industry we’re taking a look at the discontinuation of umibecestat and Acthar® Gel for Alzheimer’s and ALS, respectively, as well as the drug discovery shift from the amyloid approach in the Alzheimer’s field.
As part of our Spotlight on organoids, we carried out a survey to gain an insight into how organoids are being used as a research tool in the lab, the challenges involved in organoid research and what researchers thought about the terms ‘mini-brains’ and ‘brains in a dish’. Find out the results in this informative infographic.
To mark World Parkinson’s Day, we’re taking the opportunity to look back on some of the research highlights in the field over the last year.
Here we review your favorite and most-read pieces from all five of our partnered journals in 2018, giving you access to the most popular articles over the last year.
Want to find out what’s been happening this year? Editor, Sharon Salt, highlights the best of 2018’s neuroscience and neurology research in an A–Z.